SS-31 (Elamipretide) Mitochondrial Peptide Research Guide 2026

Among the mitochondria-targeted compounds studied over the past two decades, few have accumulated a preclinical literature as focused as SS-31, the aromatic-cationic tetrapeptide better known by its generic name elamipretide. Where most antioxidants disperse throughout the cell, SS-31 was designed by Hazel Szeto and Peter Schiller to do something narrower: concentrate at the inner mitochondrial membrane and bind cardiolipin, the signature phospholipid that organizes the machinery of cellular energy. This guide surveys the molecular profile, the receptor- and pathway-level mechanism, and the published preclinical record for SS-31 as a research compound — and how to evaluate the analytical documentation before any material enters a laboratory workflow.

The information below is provided strictly for in-vitro and preclinical research context. Nothing here describes human use, dosing, or therapeutic outcomes. SS-31 is discussed only as a laboratory research compound.

Section 1 — Molecular Profile

SS-31 is a synthetic tetrapeptide belonging to the Szeto-Schiller (SS) family of mitochondria-penetrating, aromatic-cationic peptides. Its defining structural feature is an alternating motif of aromatic and basic residues, which gives the molecule its selective membrane behavior.

• Compound name: SS-31 (elamipretide; also referenced in the literature as MTP-131 and Bendavia)
• CAS number: 736992-21-5
• Molecular formula: C32H49N9O5
• Molecular weight: approximately 639.78 g/mol
• Sequence: H-D-Arg-Dmt-Lys-Phe-NH2, where Dmt denotes 2′,6′-dimethyltyrosine
• Net charge: formally +3 at physiological pH

The use of a D-arginine residue and the dimethylated tyrosine distinguishes SS-31 from a conventional linear peptide and contributes to its metabolic stability in experimental systems. The peptide is typically supplied to laboratories as a lyophilized powder for reconstitution in a research setting.

Section 2 — Mechanism at the Pathway and Receptor Level

SS-31 is studied as a cardiolipin-interacting peptide rather than a receptor agonist. Cardiolipin is a four-tailed phospholipid found almost exclusively in the inner mitochondrial membrane, where it scaffolds the respiratory supercomplexes of the electron transport chain and helps maintain cristae curvature. Because cardiolipin is uniquely enriched at this membrane, a compound with affinity for it will localize there.

Published mechanistic work describes several converging features. First, despite a strong positive charge, SS peptides traverse the plasma membrane in an energy-independent, non-saturable manner and then accumulate at the inner mitochondrial membrane at concentrations reported to be several thousand-fold higher than the surrounding cytosol (Zhao et al., Journal of Biological Chemistry, 2004). Second, once localized, SS-31 associates with cardiolipin and modulates the interaction between cardiolipin and cytochrome c. Birk and colleagues reported that this interaction is studied for its capacity to preserve the electron-carrying function of cytochrome c while limiting the peroxidase activity of the cytochrome c/cardiolipin complex — the reaction implicated in cardiolipin peroxidation (Birk et al., Journal of the American Society of Nephrology, 2013).

More recent biophysical work has examined how the peptide sits within the lipid bilayer. Mitchell and colleagues characterized SS-31 as binding lipid bilayers and modulating membrane surface electrostatics, proposing this as a central component of its mechanism rather than simple radical scavenging alone (Journal of Biological Chemistry, 2020). Taken together, the pathway-level description that recurs across this literature is stabilization of cristae architecture, support of electron transport chain organization, and reduction of reactive oxygen species generated at the membrane. These are in-vitro and preclinical observations about mitochondrial physiology, not statements about any organism-level outcome.

Section 3 — Preclinical Research Data

The preclinical record for SS-31 spans isolated mitochondria, cultured cells, and rodent models. At the level of isolated systems, the peptide has been reported to scavenge hydrogen peroxide and peroxynitrite and to inhibit mitochondrial permeability transition and swelling in the low-nanomolar range, consistent with its high-affinity cardiolipin association (Zhao et al., 2004). This concentration profile is frequently cited as evidence that the compound acts through targeted membrane localization rather than bulk antioxidant chemistry.

Why the low-nanomolar figure matters is worth spelling out. A compound that only quenches free radicals in bulk solution would need to reach high concentrations to compete with the cell’s own antioxidant systems. SS-31’s reported activity at far lower concentrations is consistent with a targeting mechanism: because the peptide accumulates thousands-fold at the inner membrane, a small extracellular amount produces a large local effect precisely where cardiolipin and the respiratory chain sit. This is the interpretive thread that runs through the Szeto laboratory’s work — that localization, not raw scavenging capacity, is the operative variable. It is also why in-vitro assays of SS-31 are usually designed around isolated or permeabilized mitochondria, where membrane localization can be observed directly rather than inferred.

In rodent models of mitochondrial dysfunction, several groups have examined SS-31 in the context of cardiac and metabolic tissue. A murine model of Barth syndrome — a genetic disorder of cardiolipin remodeling — reported that SS-31 treatment was associated with changes in cardiac mitochondrial morphology and mitophagy markers (Scientific Reports, 2024). Aging-focused rodent work has likewise been published: long-term treatment studies in mice have examined healthy-aging phenotypes and mitochondrial endpoints (Aging Cell / GeroScience literature, 2022–2023), and an intermittent-dosing study reported effects on exercise tolerance measures in aged female mice (GeroScience, 2023). These are animal-model findings reported for research interpretation; they are described here without extrapolation to humans.

Section 4 — Published Literature

The following peer-reviewed sources anchor the SS-31 research literature and can be located through PubMed and the publishing journals:

• Zhao K, et al. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry (PubMed 15178689).
• Birk AV, et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8):1250–1261.
• Szeto HH. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8):2029–2050.
• Mitchell W, et al. (2020). The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics as a key component of its mechanism of action. Journal of Biological Chemistry (PMC7247319).
• Roshanravan B, et al. (2021). In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLOS One.
• (2024). SS-31 treatment ameliorates cardiac mitochondrial morphology and defective mitophagy in a murine model of Barth syndrome. Scientific Reports.

Researchers evaluating this compound should read the primary sources directly rather than relying on secondary summaries, as the mechanistic nuance — particularly the distinction between cardiolipin binding, cytochrome c modulation, and general antioxidant activity — is central to interpreting any downstream experiment.

Section 5 — Research Applications

Within an in-vitro and preclinical context, SS-31 appears in the literature primarily as a tool compound for interrogating mitochondrial membrane biology. Reported laboratory use cases include probing cardiolipin–cytochrome c interactions in isolated mitochondria, studying electron transport chain organization and supercomplex assembly, measuring reactive oxygen species dynamics at the inner membrane, and serving as a reference mitochondria-targeted peptide in comparative bioenergetics assays. Because the peptide localizes so strongly to the inner mitochondrial membrane, it is also used to study membrane electrostatics and cristae morphology. All such applications are laboratory research contexts; none constitute human, veterinary, or diagnostic use.

Section 6 — How to Evaluate a Source

Mitochondria-targeted peptides are only as useful as their analytical documentation. A tetrapeptide with two non-standard residues (D-arginine and dimethyltyrosine) is a synthesis where identity and purity genuinely matter, because truncated or mis-incorporated sequences will not behave like the intended molecule at the membrane. When evaluating any supplier of a research compound like SS-31, a laboratory should ask for lot-specific analytical data rather than a generic specification sheet: a purity determination by HPLC, an identity confirmation by mass spectrometry that matches the expected molecular weight, endotoxin testing appropriate to cell-based work, and heavy-metals screening. The document should name the accredited laboratory that tested that specific batch, and it should be independently verifiable rather than a static PDF that cannot be traced back to a lab portal.

Section 7 — PYXAX Verification Standard

PYXAX uses accredited independent laboratories in its verification network, including ILS Labs, Krause Analytical, and Janoshik. The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. A lot-specific COA is published in the COA Library before dispatch and names the laboratory that tested that batch. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel.

The current per-batch panel covers purity by HPLC, potency against label claim, and identity by LC-MS. Endotoxin, heavy-metals, and final-vial sterility screening are not part of the current panel. Available lot-specific records are published in the COA Library, and each dispatched lot must have its COA published before dispatch. Researchers can also review the PYXAX verification standard or browse the PYXAX shop.

The point of this standard is simple: a mitochondria-targeted tetrapeptide is a demanding synthesis, and the only way to know a lot is what it claims to be is to see the batch-specific analytical file for that lot.

---

All PYXAX compounds are supplied strictly for in-vitro and preclinical laboratory research use only. Not for human consumption. Not for veterinary use. Not for diagnostic procedures. These statements have not been evaluated by the FDA. Researchers are responsible for compliance with all applicable laws and regulations governing the use of research compounds in their jurisdiction.